Initial panic over the MFN drug pricing scheme was based on pegging U.S. prices to the lowest in the industrialized world. The actual proposal is far less drastic, targeting the second-lowest price among a small cohort of high-income nations (G7 plus Denmark and Switzerland), a significantly less onerous benchmark.

The administration is leveraging the U.S.'s market power to demand "most favored nation" pricing from pharmaceutical companies. This forces them to offer drugs at the lowest price available in any other developed nation, slashing costs for American consumers.

While MFN pricing is seen as a major threat, it could have an unexpected positive effect. It would force companies launching new drugs to establish a GDP-adjusted global price from the start, ending the current system where the U.S. effectively subsidizes lower prices elsewhere.

To fix the R&D funding imbalance, the CEO proposes a 'one fair price' system. A drug would have one US price with no rebates, and a price in other developed nations would be indexed to their GDP per capita.

The gap between U.S. and international drug prices is a structural feature of the pharma economy. High profits from the U.S. market fund expensive R&D that ultimately benefits the rest of the world, which pays far less for the same innovations. This reframes the debate around high American healthcare costs.

The Most Favored Nation (MFN) policy forces a difficult choice: launch early in Europe and risk a lower US reference price, or delay the European launch to protect US revenue, slowing patient access. This dilemma upends traditional global launch strategies, creating commercial, ethical, and operational problems for pharma companies.

Europe's ability to pay more for innovative drugs is severely constrained by inflation, high energy costs, increased defense spending, and revenue loss to US tech giants. This economic pressure may prevent US MFN policies from succeeding, potentially forcing European countries to limit patient access rather than raise prices.

The Most Favored Nation (MFN) policy was strategically designed to be disruptive. The aim was less about implementing a specific pricing framework and more about forcing the pharmaceutical industry to change its behavior, re-evaluate global strategies, and engage in new types of negotiations, which has already proven effective.

MFN's pressure on global pricing will change how innovation is valued. Truly disruptive drugs may command higher prices ex-US, while incremental "me-too" drugs in crowded classes will not. This will force pharma companies to shift R&D investment away from iterative improvements and toward therapies with radical treatment-disrupting potential.